Header Logo

Connection

Allison Naleway to United States

Back to Details
This is a "connection" page, showing publications Allison Naleway has written about United States.
Allison Naleway
Connection Strength
2.420
United States
  1. Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons. Vaccine. 2025 Oct 03; 64:127667.
    View in: PubMed
    Score: 0.133
  2. Vaccination During Pregnancy in the Vaccine Safety Datalink, 2002-2022. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S105-S107.
    View in: PubMed
    Score: 0.128
  3. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA. 2024 02 06; 331(5):408-416.
    View in: PubMed
    Score: 0.119
  4. CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design. BMJ Open. 2023 Jul 14; 13(7):e071446.
    View in: PubMed
    Score: 0.115
  5. Medically Attended Influenza During Pregnancy in the 2019-2020 and 2020-2021 Influenza Seasons. Obstet Gynecol. 2022 11 01; 140(5):874-877.
    View in: PubMed
    Score: 0.109
  6. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.108
  7. Influenza Vaccination During Pregnancy: Influenza Seasons 2002-2012, Vaccine Safety Datalink. Am J Prev Med. 2016 Apr; 50(4):480-488.
    View in: PubMed
    Score: 0.067
  8. Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events. Vaccine. 2014 Sep 03; 32(39):4985-92.
    View in: PubMed
    Score: 0.062
  9. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011. J Adolesc Health. 2013 Nov; 53(5):637-41.
    View in: PubMed
    Score: 0.059
  10. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine. 2013 Jun 12; 31(27):2898-903.
    View in: PubMed
    Score: 0.057
  11. Risk of immune hemolytic anemia in children following immunization. Vaccine. 2009 Dec 09; 27(52):7394-7.
    View in: PubMed
    Score: 0.044
  12. Delivering influenza vaccine to pregnant women. Epidemiol Rev. 2006; 28:47-53.
    View in: PubMed
    Score: 0.035
  13. Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults. JAMA Netw Open. 2025 06 02; 8(6):e2517402.
    View in: PubMed
    Score: 0.033
  14. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged =18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):73-82.
    View in: PubMed
    Score: 0.032
  15. Protection From COVID-19 Vaccination and Prior SARS-CoV-2 Infection Among Children Aged 6 Months-4 Years, United States, September 2022-April 2023. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).
    View in: PubMed
    Score: 0.032
  16. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
    View in: PubMed
    Score: 0.031
  17. Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers. Vaccine. 2024 Oct 24; 42(24):126288.
    View in: PubMed
    Score: 0.031
  18. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.031
  19. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
    View in: PubMed
    Score: 0.030
  20. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 09 07; 41(39):5678-5682.
    View in: PubMed
    Score: 0.029
  21. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
    View in: PubMed
    Score: 0.029
  22. Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res. 2003 Apr; 1(2):87-92.
    View in: PubMed
    Score: 0.028
  23. Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
    View in: PubMed
    Score: 0.028
  24. Rotavirus Vaccine Impact Within an Integrated Healthcare Delivery System in the United States. J Pediatric Infect Dis Soc. 2022 Dec 28; 11(12):586-589.
    View in: PubMed
    Score: 0.028
  25. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. JAMA. 2022 10 18; 328(15):1523-1533.
    View in: PubMed
    Score: 0.027
  26. Travelers and travel vaccines at six health care systems in the Vaccine Safety Datalink. Vaccine. 2022 09 29; 40(41):5904-5911.
    View in: PubMed
    Score: 0.027
  27. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 18; 71(11):422-428.
    View in: PubMed
    Score: 0.026
  28. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.026
  29. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.026
  30. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.026
  31. Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems. Vaccine. 2022 01 31; 40(5):752-756.
    View in: PubMed
    Score: 0.026
  32. A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016. Vaccine. 2021 12 20; 39(52):7598-7605.
    View in: PubMed
    Score: 0.026
  33. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.026
  34. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
    View in: PubMed
    Score: 0.025
  35. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.025
  36. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jun 18; 70(24):895-899.
    View in: PubMed
    Score: 0.025
  37. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 02; 70(13):495-500.
    View in: PubMed
    Score: 0.025
  38. Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol. 2020 12; 136(6):1086-1094.
    View in: PubMed
    Score: 0.024
  39. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23; 69(38):1355-1359.
    View in: PubMed
    Score: 0.024
  40. Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016-17 season. Vaccine. 2020 02 24; 38(9):2202-2208.
    View in: PubMed
    Score: 0.023
  41. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
    View in: PubMed
    Score: 0.022
  42. Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.022
  43. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine. 2019 06 27; 37(29):3918-3924.
    View in: PubMed
    Score: 0.022
  44. Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine. 2019 05 31; 37(25):3296-3302.
    View in: PubMed
    Score: 0.021
  45. Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics. 2018 03; 141(3).
    View in: PubMed
    Score: 0.020
  46. Estimated rates of influenza-associated outpatient visits during 2001-2010 in 6 US integrated healthcare delivery organizations. Influenza Other Respir Viruses. 2018 01; 12(1):122-131.
    View in: PubMed
    Score: 0.020
  47. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
    View in: PubMed
    Score: 0.020
  48. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
    View in: PubMed
    Score: 0.019
  49. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
    View in: PubMed
    Score: 0.019
  50. Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
    View in: PubMed
    Score: 0.018
  51. Risk of Preterm or Small-for-Gestational-Age Birth After Influenza Vaccination During Pregnancy: Caveats When Conducting Retrospective Observational Studies. Am J Epidemiol. 2016 08 01; 184(3):176-86.
    View in: PubMed
    Score: 0.018
  52. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population. Vaccine. 2015 Aug 26; 33(36):4446-50.
    View in: PubMed
    Score: 0.017
  53. Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. J Infect Dis. 2015 Dec 15; 212(12):1970-5.
    View in: PubMed
    Score: 0.016
  54. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. Mayo Clin Proc. 2015 Jul; 90(7):865-73.
    View in: PubMed
    Score: 0.016
  55. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015 Feb; 135(2):e321-9.
    View in: PubMed
    Score: 0.016
  56. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine. 2015 Jan 03; 33(2):382-7.
    View in: PubMed
    Score: 0.016
  57. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014 Sep 22; 32(42):5390-8.
    View in: PubMed
    Score: 0.015
  58. Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites. Prev Med. 2014 Oct; 67:316-9.
    View in: PubMed
    Score: 0.015
  59. Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014 Jun; 133(6):e1492-9.
    View in: PubMed
    Score: 0.015
  60. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf. 2014 May; 23(5):548-53.
    View in: PubMed
    Score: 0.015
  61. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014 Feb 06; 370(6):513-9.
    View in: PubMed
    Score: 0.015
  62. Safety of the yellow Fever vaccine: a retrospective study. J Travel Med. 2013 Nov-Dec; 20(6):368-73.
    View in: PubMed
    Score: 0.015
  63. Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic. Am J Epidemiol. 2013 Oct 15; 178(8):1327-36.
    View in: PubMed
    Score: 0.014
  64. Mortality rates and cause-of-death patterns in a vaccinated population. Am J Prev Med. 2013 Jul; 45(1):91-97.
    View in: PubMed
    Score: 0.014
  65. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31(22):2578-83.
    View in: PubMed
    Score: 0.014
  66. A population-based cohort study of undervaccination in 8 managed care organizations across the United States. JAMA Pediatr. 2013 Mar 01; 167(3):274-81.
    View in: PubMed
    Score: 0.014
  67. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. Obstet Gynecol. 2013 Mar; 121(3):519-25.
    View in: PubMed
    Score: 0.014
  68. Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics. 2013 Feb; 131(2):283-9.
    View in: PubMed
    Score: 0.014
  69. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis. 2013 Feb; 56(3):315-21.
    View in: PubMed
    Score: 0.014
  70. Assessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalink. Am J Obstet Gynecol. 2012 Sep; 207(3 Suppl):S47-51.
    View in: PubMed
    Score: 0.013
  71. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respir Viruses. 2012 Nov; 6(6):e143-51.
    View in: PubMed
    Score: 0.013
  72. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012 May; 129(5):809-14.
    View in: PubMed
    Score: 0.013
  73. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med. 2011 Aug; 41(2):121-8.
    View in: PubMed
    Score: 0.013
  74. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011 Aug; 165(8):749-55.
    View in: PubMed
    Score: 0.013
  75. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011 May; 127 Suppl 1:S45-53.
    View in: PubMed
    Score: 0.012
  76. The Pregnancy and Influenza Project: design of an observational case-cohort study to evaluate influenza burden and vaccine effectiveness among pregnant women and their infants. Am J Obstet Gynecol. 2011 Jun; 204(6 Suppl 1):S69-76.
    View in: PubMed
    Score: 0.012
  77. Injection site and risk of medically attended local reactions to acellular pertussis vaccine. Pediatrics. 2011 Mar; 127(3):e581-7.
    View in: PubMed
    Score: 0.012
  78. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
    View in: PubMed
    Score: 0.011
  79. Validation of a screening instrument to identify persons for exclusion from smallpox vaccination. Clin Infect Dis. 2005 Feb 15; 40(4):620-3.
    View in: PubMed
    Score: 0.008
  80. Detecting possible vaccination reactions in clinical notes. AMIA Annu Symp Proc. 2005; 306-10.
    View in: PubMed
    Score: 0.008

© 2025 Kaiser Permanente

Your Privacy Choices